COVID-19's Impact on Lab Industry Testing Volumes and Dynamics - January 2021 Update
UBS invites you to listen to the 1 hour audio conference recording, "COVID-19's Impact on Lab Industry Testing Volumes and Dynamics - January 2021 Update," to hear UBS Research Analysts and XIFIN Executives discuss the latest impacts in the short and long term, that COVID-19 has had on the laboratory and diagnostic testing industry.
Learn how Laboratory and Diagnostic Testing Volumes have trended through the end of the year into early 2021 amid the ongoing 3rd Wave as well as testing capacity/pipeline expectations from a company that processes over $40bn of gross diagnostic claims annuallyLearn how the COVID-19 outbreak has impacted diagnostic volumes, mix, and reimbursement for a variety of diagnostic providers (hospital, regional, reference, and national providers)Understand the key factors that will impact COVID PCR and Serology testing volumes in 2021, including new platforms/instruments, direct to consumer tests coming on line, and expectations for PCR and Serology testing demand as the COVID Vaccine roll out continuesUnderstand the financial conditions of the variety of diagnostic providers and how the COVID-19 outbreak might impact industry dynamics (National Labs, Hospital Labs, and Independent Labs) including Genetics/Infectious Disease Testing, M&A, and insourcing/outsourcing decision-making
Insight into reimbursement dynamics for COVID PCR testing (Medicare, Medicaid, and Commercial) as well as industry efforts with regards to PAMA
- Kevin Caliendo, UBS Healthcare Supply Chain & HCIT Senior Analyst
- Dan Brennan, UBS Life Science Tools & Diagnostics Senior Analyst
- Matt Taylor, CFA, UBS US Medical Supplies & Devices
- Whit Mayo, UBS Healthcare Services and Managed Care Analyst